Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Core Scientific (CORZ) Liabilities and Shareholders Equity (2020 - 2025)

Core Scientific's Liabilities and Shareholders Equity history spans 6 years, with the latest figure at $2.2 billion for Q3 2025.

  • For Q3 2025, Liabilities and Shareholders Equity rose 163.32% year-over-year to $2.2 billion; the TTM value through Dec 2025 reached $3.7 billion, down 2.89%, while the annual FY2024 figure was $1.5 billion, 107.25% up from the prior year.
  • Liabilities and Shareholders Equity for Q3 2025 was $2.2 billion at Core Scientific, up from $1.5 billion in the prior quarter.
  • Across five years, Liabilities and Shareholders Equity topped out at $2.7 billion in Q1 2022 and bottomed at $347.1 million in Q3 2021.
  • The 5-year median for Liabilities and Shareholders Equity is $810.8 million (2022), against an average of $1.1 billion.
  • The largest annual shift saw Liabilities and Shareholders Equity soared 16258993.33% in 2021 before it plummeted 71.89% in 2023.
  • A 5-year view of Liabilities and Shareholders Equity shows it stood at $2.4 billion in 2021, then plummeted by 66.88% to $807.7 million in 2022, then dropped by 11.83% to $712.2 million in 2023, then soared by 107.25% to $1.5 billion in 2024, then surged by 47.11% to $2.2 billion in 2025.
  • Per Business Quant, the three most recent readings for CORZ's Liabilities and Shareholders Equity are $2.2 billion (Q3 2025), $1.5 billion (Q1 2025), and $1.5 billion (Q4 2024).